Fortescue edges lower as iron ore pulls back, China weighs on FMG

Fortescue edges lower as iron ore pulls back, China weighs on FMG

June 16, 2026

Sydney, June 17, 2026, 05:06 (AEST).

  • Fortescue dropped 1.34% to finish at A$20.54 on Tuesday. The S&P/ASX 200 edged up 0.04% to 8,917.7.
  • Iron ore stocks traded lower with SGX iron ore futures down 0.7% to US$101.25 per tonne.
  • Fortescue reports June-quarter production on July 31. Investors will watch those numbers.

Fortescue Ltd slipped 1.3% to finish at A$20.54 on the ASX Tuesday, hitting its session low. Shares moved between A$20.54 and A$20.90. The S&P/ASX 200 eked out a 3.7-point gain. Banks and energy names offset weaker materials. Iron ore stocks came under pressure after SGX iron ore futures dropped 0.7% to US$101.25 a tonne, according to Market Index.

Fortescue is still struggling with China. Reuters said Tuesday that major iron ore miners are now looking to India and Southeast Asia for new growth since China’s steel buyers aren’t moving. Chinese steel demand is expected to drop again this year, according to Reuters. Last month, China Mineral Resources Group turned up the heat on Fortescue as well. Fortescue depends on iron ore prices and contract deals, so weak demand and harder negotiations with China can weigh on the stock fast.

Fortescue reported iron ore shipments of 48.4 million tonnes for the March quarter, with nine-month volumes hitting a record 148.7 million tonnes. Hematite C1 unit costs landed at US$18.29 a tonne. The miner held its FY26 guidance steady at 195 million to 205 million tonnes. Cost control and a steady dividend have kept income investors interested, as long as iron ore prices don’t fall. The bullish story here is simple.

Bears got more ammo here. Iron Bridge lowered its shipment outlook to 9-10 million tonnes, blaming weather. Net debt stood at US$1.6 billion as of March 31. Fortescue is still pouring money into metals and energy projects and putting cash toward cutting emissions. The Green Metal Project at Christmas Creek looks set for first hot metal output this quarter. That puts the company on the hook to back up its talk with results in green iron, not just future plans.

Fortescue reached a new deal with the Puutu Kunti Kurrama and Pinikura Traditional Owners, setting out fresh Native Title and Co-Management rules for mining, heritage, and business on PKKP land. Pinikura Traditional Owner Terry Drage said PKKP will be “not as a silent partner, but as a true partner.” The agreements set clearer terms for heritage and co-management. For investors, that means potential for less project risk in the Pilbara. Global

Fortescue shares are around A$20.54. That’s not especially cheap. The stock trades on a price/earnings ratio of 11.94, with a 5.94% dividend yield based on data from Google Finance. Analysts remain divided—of nine tracked, two say buy, three have holds, and four are on sell. Their average 12-month price target is A$19.31, lower than the current price. Price targets only offer estimates. The market is watching Fortescue’s July 31 production numbers next, with interest on Iron Bridge output, C1 costs, China contract talks, and the FY26 results set for August 24.

Stock Market Today

  • Entropy Neurodynamics Accelerates Psychedelic Medicine Trials Amid FDA Developments
    June 16, 2026, 5:56 PM EDT. Entropy Neurodynamics (ASX:ENP) advances phase II trials for its psilocin-based drug targeting binge eating disorder (BED), a condition with complex mental and behavioral symptoms. CEO Jason Carroll supports the imminent FDA approval of Compass Pathways' psilocybin therapy for treatment-resistant depression, which could establish the first regulated psychedelic treatment in the U.S. Recent regulatory easing promises quicker approvals by reducing previous DEA constraints. Entropy's collaboration with Swinburne University shows safety in initial cohorts, with results expected by July. BED's significant treatment challenges highlight the potential impact of Entropy's innovative therapy. The evolving landscape signals growing momentum for psychedelic medicines addressing mental health disorders.